IP Library Patent Application 12100382
Patent Application
App. No. 12/100,382

Methods and Compositions For Treating Sleep-Related Breathing Disorders

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/100,382
Abstract

Provided herein are methods of treating a sleep-related breathing disorder, such as obstructive sleep apnea, comprising the administration of O-desmethylvenlafaxine or duloxetine.

Claims (12)

1 . A method of treating a sleep-related breathing disorder in a patient, comprising administering to a patient a therapeutically effective amount of O-desmethylvenlafaxine, or a pharmaceutically acceptable salt or solvate thereof.

2 . The method of claim 1 , wherein the O-desmethylvenlafaxine is enriched for the (+) enantiomer.

3 . The method of claim 2 , wherein the O-desmethylvenlafaxine is enriched for the (−) enantiomer.

4 . The method of claim 3 , wherein the O-desmethylvenlafaxine is substantially free of (+)-O-desmethylvenlafaxine.

5 . The method of claim 1 , wherein the O-desmethylvenlafaxine is administered conjointly with a second active agent, wherein said second active agent is a sleep enhancer, an agent that treats excessive daytime drowsiness, an anti-obesity agent, or an agent that stabilizes respiratory drive.

6 . The method of claim 1 , wherein the O-desmethylvenlafaxine is administered conjointly with positive airway pressure treatment.

7 . The method of claim 1 , wherein the O-desmethylvenlafaxine is administered orally, sublingually, or by oral inhalation.

8 . A method of treating a sleep-related breathing disorder in a patient, comprising administering to a patient a therapeutically effective amount of duloxetine, or a pharmaceutically acceptable salt or solvate thereof.

9 . The method of claim 8 , wherein the duloxetine is administered conjointly with a second active agent, wherein said second active agent is a sleep enhancer, an agent that treats excessive daytime drowsiness, an anti-obesity agent, or an agent that stabilizes respiratory drive.

10 . The method of claim 8 , wherein the duloxetine is administered conjointly with positive airway pressure treatment.

11 . The method of claim 8 , wherein the duloxetine is administered orally, sublingually, or by oral inhalation.

12 . The method of claim 8 , wherein the sleep-related breathing disorder is obstructive sleep apnea.

Assignments (2)
CHANGE OF NAME Recorded Feb 24, 2011
From: SEPRACOR INC.
To: SUNOVION PHARMACEUTICALS INC.
Reel/Frame 025860/0392 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2008
From: HANDLEY, DEAN A.; HARDY, LARRY W.; PARSEY, MERDAD VAZIRI
To: SEPRACOR INC.
Reel/Frame 021359/0231 →